Case-Based Roundtable Meeting Spotlight October 1 2021

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was was later diagnosed with NSCLC.

A 78-year-old White woman was given a diagnosis of stage II multiple myeloma and was deemed transplant ineligible. Genetic testing showed deletion 17p.

In a patient case reviewed by Gilberto De Lima Lopes, MD, a 59-year-old man presented with chest pain, cough, and dyspnea.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old woman with diffuse large B-cell lymphoma complained of fever, night sweats, and back pain.

A 77-year-old woman presented to her primary care physician complaining of abdominal pain and fatigue. Ghassan K. Abou-Alfa, MD, discussed the case with a group of physicians.

A 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

A patient with metastatic castration-resistant prostate cancer received external beam radiation therapy and androgen deprivation therapy became asymptomatic, then presented with hip pain and urinary frequency 6 months later.

During separate virtual live events, Matthew A. Gubens, MD, MS, and Rodolfo Bordoni, MD, discussed the CASPIAN trial of durvalumab plus platinum therapy and etoposide and whether the participants have used this regimen in patients with small cell lung cancer.

David I. Quinn, MD, MBBS, PhD and other oncologists, discussed disease management and the option of using an osteoclast-targeting agent for a 75-year-old man with metastatic castration-resistant prostate cancer.

A 51-year-old patient who originally presented with pallor and worsening fatigue on exertion was diagnosed with standard-risk, stage II multiple myeloma.